Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
Lack Of Clarity Over FDA Expectations And Mid-Cycle Changes Add To Challenges
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
